Core Viewpoint - The "2024-2025 Family Essential Medicine Brand Awards" event recognized key pharmaceutical brands, emphasizing the importance of quality and consumer trust in the healthcare sector [1][2] Group 1: Event Overview - The award ceremony took place on November 18 during the "91st National Pharmaceutical Trade Fair" in Nanjing, highlighting its status as a benchmark in family health medication [1] - The selection process involved rigorous qualification checks, market surveys, public voting, and professional evaluations to ensure product quality and reputation [1] Group 2: Company Achievements - Linuo Pharmaceutical won three significant awards, including the "Consumer Favorite Enterprise Award," showcasing its brand strength and market reputation [1] - The company's core product, Furuisi Ammonium Lignosulfonate Paste, was recognized as a top brand in the "Oral and Throat Medicine" category, while the Xinshu Nitroglycerin Spray was listed in the "Cardiovascular Medicine" category [1] Group 3: Company Background and Future Plans - Established in 2002, Linuo Pharmaceutical is a wholly-owned subsidiary of Kexin Pharmaceutical (stock code: 301281.SZ) and is recognized as a high-tech enterprise with significant growth potential in the Chinese pharmaceutical industry [1][2] - The company has accelerated its digital transformation, establishing three intelligent manufacturing bases and creating a diverse product matrix, which includes various dosage forms [2] - Future plans include continuous product upgrades and innovative research to align with the "Healthy China" strategy, aiming to enhance public health and maintain consumer trust [2]